Therapeutic Controversies in Spondyloarthritis Nonsteroidal Anti-Inflammatory Drugs

被引：20
作者：
Poddubnyy, Denis [1 ]
van der Heijde, Desiree [2 ]
机构：
[1] Charite, Dept Med 1, D-12203 Berlin, Germany
[2] Leiden Univ, Med Ctr, Dept Rheumatol, NL-2300 RC Leiden, Netherlands
来源：
RHEUMATIC DISEASE CLINICS OF NORTH AMERICA | 2012年 / 38卷 / 03期
关键词：
Spondyloarthritis; Ankylosing spondylitis; ASAS; Nonsteroidal anti-inflammatory drugs; Therapy; ACTIVE ANKYLOSING-SPONDYLITIS; RANDOMIZED CONTROLLED-TRIAL; OPEN-LABEL TRIAL; AXIAL SPONDYLOARTHRITIS; RADIOGRAPHIC PROGRESSION; ASAS/EULAR RECOMMENDATIONS; RHEUMATOID-ARTHRITIS; ASAS RECOMMENDATIONS; ULCER COMPLICATIONS; SPINAL MOBILITY;
D O I：
10.1016/j.rdc.2012.08.005
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Nonsteroidal anti-inflammatory drugs (NSAIDs) are considered a first-line therapy in patients with axial spondyloarthritis (axSpA), including ankylosing spondylitis. NSAIDs reduce pain and stiffness effectively in most patients, are able to reduce systemic and local inflammation, and can inhibit progression of structural damage in the spine. However, effective control of symptoms and retardation of radiographic progression often require continuous and long-term treatment, which raises safety concerns. This article discusses controversies related to the current role of NSAIDs in axSpA treatment, risks and benefits of this treatment, and current trends for individualized treatment.
引用
收藏
页码：601 / +
页数：12
相关论文
共 47 条
[1]  
AMOR B, 1995, REV RHUM, V62, P10
[2]   Increased mortality in ankylosing spondylitis is related to disease activity [J].
Bakland, Gunnstein ;
Gran, Jan Tore ;
Nossent, Johannes C. .
ANNALS OF THE RHEUMATIC DISEASES, 2011, 70 (11) :1921-1925
[3]  
Barkhuizen A, 2006, J RHEUMATOL, V33, P1805
[4]   Prostaglandins in bone: bad cop, good cop? [J].
Blackwell, Katherine A. ;
Raisz, Lawrence G. ;
Pilbeam, Carol C. .
TRENDS IN ENDOCRINOLOGY AND METABOLISM, 2010, 21 (05) :294-301
[5]  
BOERSMA JW, 1976, SCAND J RHEUMATOL, V5, P60
[6]   Identifying patients with axial spondyloarthritis in primary care: how useful are items indicative of inflammatory back pain? [J].
Braun, A. ;
Saracbasi, E. ;
Grifka, J. ;
Schnitker, J. ;
Braun, J. .
ANNALS OF THE RHEUMATIC DISEASES, 2011, 70 (10) :1782-1787
[7]   2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis [J].
Braun, J. ;
van den Berg, R. ;
Baraliakos, X. ;
Boehm, H. ;
Burgos-Vargas, R. ;
Collantes-Estevez, E. ;
Dagfinrud, H. ;
Dijkmans, B. ;
Dougados, M. ;
Emery, P. ;
Geher, P. ;
Hammoudeh, M. ;
Inman, R. D. ;
Jongkees, M. ;
Khan, M. A. ;
Kiltz, U. ;
Kvien, T. K. ;
Leirisalo-Repo, M. ;
Maksymowych, W. P. ;
Olivieri, I. ;
Pavelka, K. ;
Sieper, J. ;
Stanislawska-Biernat, E. ;
Wendling, D. ;
Ozgocmen, S. ;
van Drogen, C. ;
van Royen, B. J. ;
van der Heijde, D. .
ANNALS OF THE RHEUMATIC DISEASES, 2011, 70 (06) :896-904
[8]   Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison [J].
Cannon, Christopher P. ;
Curtis, Sean P. ;
FitzGerald, Garret A. ;
Krum, Henry ;
Kaur, Amarjot ;
Bolognese, James A. ;
Reicin, Alise S. ;
Bombardier, Claire ;
Weinblatt, Michael E. ;
van der Heijde, Desiree ;
Erdmann, Erland ;
Laine, Loren .
LANCET, 2006, 368 (9549) :1771-1781
[9]   Assessment of outcome in ankylosing spondylitis: an extended radiographic scoring system [J].
Creemers, MCW ;
Franssen, MJAM ;
van't Hof, MA ;
Gribnau, FWJ ;
van de Putte, LBA ;
van Riel, PLCM .
ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 (01) :127-129
[10]   Ankylosing spondylitis: what is the optimum duration of a clinical study? A one year versus a 6 weeks non-steroidal anti-inflammatory drug trial [J].
Dougados, M ;
Gueguen, A ;
Nakache, JP ;
Velicitat, P ;
Veys, EM ;
Zeidler, H ;
Calin, A .
RHEUMATOLOGY, 1999, 38 (03) :235-244
12345